title: [Role of nitric oxide system in pathogenesis of experimental model of hepatorenal syndrome].
abstract: Hepatorenal syndrome (HRS) is still one of a few great secrets of today's medicine. Pathomechanism of this syndrome, specially in case of an acute liver damage, is still poorly understood.
  
  
  OBJECTIVE
  In our study in experimental galactosamine (Ga1N) model, using the nitric oxide synthase (NOS) inhibitor- N omega-nitro-L-Arginine (L-NAME), we tried to explain, whether the nitric oxide plays some role in this model of HRS.
  
  
  METHODS
  We used 56 male Sprague-Dawley rats (SDR) divided into 7 groups. To achieve acute renal failure in all tested groups of animals GalN was given intraperitoneally. To determine influence of nitric oxide inhibition, L-NAME was given before and after Ga1N injection. Control groups received adequate volume of 0.9% saline solution.
  
  
  RESULTS
  Liver and renal failure developed in all tested groups. Inhibition of NOS significantly but dose independently prevented the development of acute renal failure both before and after Ga1N injection. Pretreatment with L-NAME was significantly more succesful than post Ga1N treatment.
  
  
  CONCLUSIONS
  Our study showed that inhibition of nitric oxide synthase prevents the development of renal failure in animal model of HRS. This is probably the first observation that nitric oxide plays important role in this model of HRS.
authors.affiliation: Wojskowy Instytut Medyczny w Warszawie, CSK MON: Klinika Chorób Wewnetrznych, Nefrologii i Dializoterapii. msaracyn@wim.mil.pl
authors.forename: Marek
authors.initials: M
authors.lastname: Saracyn
authors.forename: Piotr
authors.initials: P
authors.lastname: Wesołowski
authors.forename: Zbigniew
authors.initials: Z
authors.lastname: Nowak
authors.forename: Janusz
authors.initials: J
authors.lastname: Patera
authors.forename: Wojciech
authors.initials: W
authors.lastname: Kozłowski
authors.forename: Zofia
authors.initials: Z
authors.lastname: Wańkowicz
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005688:Galactosamine / Q000633:toxicity; D006530:Hepatorenal Syndrome / Q000139:chemically induced / Q000503:physiopathology*; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000627:therapeutic use*; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D004791:Enzyme Inhibitors; D009569:Nitric Oxide; D005688:Galactosamine; D019001:Nitric Oxide Synthase; D019331:NG-Nitroarginine Methyl Ester